Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Gel-Based Proteomics of Clinical Samples Identifies Potential Serological Biomarkers for Early Detection of Colorectal Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Evaluation of algorithm development approaches: Development of biomarker panels for early detection of colorectal lesions

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prognostic factors for relapse in patients with clinical stage I testicular cancer: protocol for a Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Malignancies in the upper gastrointestinal (UGI) tract are amongst the most aggressive cancers and only few treatment options exist. We have recently analysed data from a phase II trial where patients with UGI cancers were treated with erlotinib and bevacizumab. The combination therapy could not be recommended in an unselected population of patients with chemo-refractory UGI cancer. However, a subpopulation of patients did benefit from the therapy. In this prospectively planned biomarker study we investigated vascular endothelial growth factor A (VEGF-A), VEGF receptor 2 (VEGFR-2) and epidermal growth factor receptor (EGFR) by immunohistochemistry and KRAS mutation status detected by PCR as potential predictors of effect of therapy. High VEGF-A expression was correlated to longer overall survival (HR: 0.8, 95%CI: 0.7-0.9) and high VEGFR-2 expression to shorter progression free survival (HR: 1.4, 95%CI: 1.0-1.9). EGFR expression and KRAS mutation status were not correlated to response or survival. We conclude that VEGF-A and VEGFR-2 could potentially be predictive markers in patients with UGI cancers treated with erlotinib and bevacizumab.
Original languageEnglish
JournalCancer Biology & Therapy
Volume11
Issue number8
Pages (from-to)732-9
Number of pages8
ISSN1538-4047
Publication statusPublished - Apr 2011

    Research areas

  • Adult, Aged, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Female, Gastrointestinal Neoplasms, Humans, Male, Middle Aged, Mutation, Proto-Oncogene Proteins, Quinazolines, Receptor, Epidermal Growth Factor, Survival Analysis, Treatment Outcome, Tumor Markers, Biological, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor-2, ras Proteins

ID: 33271405